Accepted Manuscript

Population pharmacokinetics of NNZ-2566 in healthy subjects



Sean P. Oosterholt, Joseph Horrigan, Nancy Jones, Larry Glass, Oscar Della Pasqua

PII:	S0928-0987(17)30260-9
DOI:	doi: 10.1016/j.ejps.2017.05.032
Reference:	PHASCI 4046
To appear in:	European Journal of Pharmaceutical Sciences
Received date:	14 May 2017
Revised date:	###REVISEDDATE###
Accepted date:	15 May 2017

Please cite this article as: Sean P. Oosterholt, Joseph Horrigan, Nancy Jones, Larry Glass, Oscar Della Pasqua, Population pharmacokinetics of NNZ-2566 in healthy subjects, *European Journal of Pharmaceutical Sciences* (2017), doi: 10.1016/j.ejps.2017.05.032

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Population pharmacokinetics of NNZ-2566 in healthy subjects

Sean P. Oosterholt¹, Joseph Horrigan², Nancy Jones², Larry Glass², Oscar Della Pasqua¹.

¹ Clinical Pharmacology & Therapeutics Group, School of Life and Medical Sciences, University College London, London, UK

² Clinical Development and Medical Affairs, Neuren Pharmaceuticals, Ltd.

*Correspondence to:

Prof Oscar Della Pasqua

Clinical Pharmacology & Therapeutics Group

University College London

BMA House, Tavistock Square

London, WC1H 9JP

United Kingdom

Email: o.dellapasqua@ucl.ac.uk

Phone: +442078741544

Key words: NNZ-2566; population pharmacokinetics; first-time-in-humans; rare diseases; phase I; modelling and simulation; trofinetide.

Download English Version:

https://daneshyari.com/en/article/8512128

Download Persian Version:

https://daneshyari.com/article/8512128

Daneshyari.com